Back to Journals » OncoTargets and Therapy » Volume 7

B7-H3 expression in breast cancer and upregulation of VEGF through gene silence

Authors Sun J, Guo Y, Li X, Zhang Y, Gu L, Wu P, Bai G, Xiao Y

Received 3 March 2014

Accepted for publication 26 June 2014

Published 29 October 2014 Volume 2014:7 Pages 1979—1986


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Jing Sun,1 Yun-Di Guo,1 Xiao-Ning Li,1 Yang-Qin Zhang,1 Li Gu,1 Ping-Ping Wu,1 Guang-Hui Bai,2 Yang Xiao1

1Suzhou Health College, Jiangsu Suzhou, People’s Republic of China; 2The Fourth Hospital of Suzhou, Jiangsu Suzhou, People’s Republic of China

Abstract: B7-H3, a novel member of the B7 family, was previously known as a regulatory ligand regulating T-cell-mediated immune response, and in recent years it was found to take a significant role in various cancers. In some tumor types, high expression of B7-H3 had been linked to a poor prognosis, whereas in other cancers the opposite effect had been observed. The precise role of B7-H3 in tumor immunity is unclear, and further investigations are needed. In the present study, we studied the expression of B7-H3 in the pathologic specimens of 221 patients treated for breast cancer by immunohistochemistry. Strong B7-H3 expression was found in cancer tissues from 80.55% patients, and B7-H3 expression had a negative relation with vascular endothelial growth factor (VEGF) expression, microvascular density for CD34, and tumor size. Furthermore, through lipopolysaccharide-mediated delivery of stable short hairpin ribonucleic acid we observed that silencing of B7-H3 could increase the transcription and secreting of VEGF in breast cancer cell line MCF-7. In summary, the present study demonstrated that B7-H3 suppressed tumor growth through inhibiting VEGF expression. These results increased knowledge of the nonimmunological role of B7-H3 protein and provided novel insights into great biological functions and a putative therapeutic target in breast cancer.

Keywords: breast cancer, B7-H3, vascular endothelial growth factor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]